Bridge Screening Programme of Frequency of Bipolar Disorders in Patients with a Major Depressive Episode with or without Certain Psychiatric Comorbid Conditions” with registration number of DIREG_R_3653, is the new field of cooperation between Sanofi-Aventis and Farzan Clinical Research. Farzan will monitor the study in a number of Iranian clinical sites.
This study is aimed to provide an estimate of the frequency of bipolar disorders in patients with the diagnosis of major depressive episode and to identify the relation between bipolar disorder and some other comorbid conditions.
Sanofi-Aventis is a French multinational pharmaceutical company headquartered in Paris, France, the world’s fourth-largest by prescription sales. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines. It is the world’s largest producer of vaccines through its subsidiary Sanofi Pasteur. With more than 110,000 employees in a hundred countries, Sanofi-Aventis has a strong presence worldwide.
Farzan Clinical Research is the first Iranian Clinical Research Organization (CRO). Farzan Clinical Research is now an important partner for many Universities, research centers, scientific societies as well as pharmaceutical and medical device industry. After 10 years experience in providing medical research services as Farzan Institute for Science, Research & Technology, Farzan Clinical Research was founded in Feb 2008 as the first Iranian registered CRO and now offers Clinical Trial Management, Clinical Trial Monitoring, Data Management, Biostatistics and Medical Writing services. Farzan Clinical Research is certified by Ministry of Health and Medical Education- Food and Drug Organization (FDA) – Islamic Republic of Iran.
